- Home
- KURA vs CHY Comparison
KURA vs CHY Comparison
Compare KURA & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KURA
- CHY
- Stock Information
- Founded
- KURA 2014
- CHY 2003
- Country
- KURA United States
- CHY United States
- Employees
- KURA N/A
- CHY N/A
- Industry
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- CHY Investment Managers
- Sector
- KURA Health Care
- CHY Finance
- Exchange
- KURA Nasdaq
- CHY Nasdaq
- Market Cap
- KURA 713.5M
- CHY 839.8M
- IPO Year
- KURA N/A
- CHY N/A
- Fundamental
- Price
- KURA $10.27
- CHY $11.72
- Analyst Decision
- KURA Strong Buy
- CHY
- Analyst Count
- KURA 13
- CHY 0
- Target Price
- KURA $25.00
- CHY N/A
- AVG Volume (30 Days)
- KURA 1.9M
- CHY 128.3K
- Earning Date
- KURA 11-04-2025
- CHY 01-01-0001
- Dividend Yield
- KURA N/A
- CHY 10.11%
- EPS Growth
- KURA N/A
- CHY N/A
- EPS
- KURA N/A
- CHY N/A
- Revenue
- KURA $83,279,000.00
- CHY N/A
- Revenue This Year
- KURA $68.63
- CHY N/A
- Revenue Next Year
- KURA $141.59
- CHY N/A
- P/E Ratio
- KURA N/A
- CHY N/A
- Revenue Growth
- KURA N/A
- CHY N/A
- 52 Week Low
- KURA $5.41
- CHY $9.97
- 52 Week High
- KURA $19.73
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- KURA 57.06
- CHY 65.35
- Support Level
- KURA $10.18
- CHY $11.60
- Resistance Level
- KURA $11.06
- CHY $11.80
- Average True Range (ATR)
- KURA 0.62
- CHY 0.16
- MACD
- KURA -0.02
- CHY 0.02
- Stochastic Oscillator
- KURA 60.35
- CHY 87.15
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.